Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:08 PM ET 8-K
Financial Results Sellas Life Sciences Group, Inc. SLS

Sellas Life Sciences Group Financial Results

SELLAS Life Sciences reported its third quarter 2026 financial results, highlighting a cash position of $134.7 million. The company expects to report topline primary endpoint results from its Phase 3 REGAL trial of GPS in AML later this month and preliminary topline data for SLS009 in first-line AML in Q4 2026.

Term
Q3 2026

“We continue to execute across both of our clinical programs as we approach several important milestones. In our ongoing Phase 3 REGAL trial of GPS, we are focused on completing the final analysis following the announcement of 80th event, and we expect to announce topline primary endpoint results this month. If successful, we believe GPS could be a transformative new immunotherapy for AML patients in second complete remission.”

Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer

“In parallel, enrollment and dosing continue in our Phase 2 trial of tambiciclib (SLS009) in newly diagnosed AML, with preliminary topline data expected in the fourth quarter. As announced earlier this month, we look forward to presenting our Phase 2 data in relapsed/refractory AML at the upcoming ASH in December. We were also encouraged by the preclinical data presented at AACR in pancreatic cancer models, including in resistance to a RAS inhibitor, and we are continuing our preparations for clinical development in that indication. With $134.7 million in cash and cash equivalents as of September 30, we are well positioned to further advance these programs.”

Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer
4:08 PM ET 8-K
Loan & Debt DTE Electric Co

DTE Electric $600M Debt Financing with U.S. Bank Trust Company, National Association

DTE Electric Securitization Funding III LLC, a subsidiary of DTE Electric Company, issued $600.46 million of Series 2026A Senior Secured Securitization Bonds. The bonds were issued under an indenture and series supplement dated November 12, 2026, to securitize certain utility properties and related rights.

Value
$600M
Counterparty
U.S. Bank Trust Company, National Association
4:08 PM ET 8-K
Financial Results Knightscope, Inc. KSCP

Knightscope Financial Results

Knightscope reported Q3 2026 revenue of $8.7 million, a 177% increase year-over-year, driven by its new Autonomous Security Force managed service strategy. The company achieved a positive gross margin of $0.4 million compared to a gross loss in the prior year, though it recorded a net loss of $11.8 million for the quarter.

Term
Q3 2026

“We delivered our third consecutive quarter of triple-digit revenue growth, and positive gross margin in our services business. This year we redefined our go-to-market strategy around delivering security outcomes - autonomous machines, AI-driven software, and licensed security agents operating as one accountable operation under one contract.”

William Santana Li, Founder, Chairman and CEO of Knightscope

“Our priorities are clear: convert the approximately $27 million in renewals, bookings, and client awards secured since May 2026 into revenue, expand with the clients we already serve, and drive margins higher.”

William Santana Li, Founder, Chairman and CEO of Knightscope
4:08 PM ET 8-K
Financial Results Streamex Corp. STEX

Streamex Financial Results

Streamex Corp. reported Q3 2026 financial results, highlighting a net loss of $17.5 million and a total liquidity position of $36.5 million. The company saw significant growth in its tokenized gold product (GLDY), with assets under management reaching $14.0 million and external ownership doubling to 17.7%.

Term
Q3 2026

“Q1 launched GLDY, Q2 built the distribution around it, and Q3 was about scaling that distribution and adoption. Over the last ninety days, an institutional investment manager began running a gold carry strategy with GLDY as its long leg, outside ownership doubled, and the Cask Foundation began bootstrapping liquidity for its first product, USGY.”

Henry McPhie, Co-Founder and Chief Executive Officer
4:08 PM ET 8-K
Financial Results Adial Pharmaceuticals, Inc. AZR

Azora Therapeutics Financial Results

Azora Therapeutics reported its third quarter 2026 financial results, highlighting its recent transition to the Nasdaq under the ticker 'AZR' and the appointment of a new executive leadership team. The company remains on track to submit an IND and initiate a Phase 1a trial for its lead candidate AT177 in the first half of 2027.

“With our transition to Nasdaq, Azora is well positioned for success to bring AhR biology to people living with ulcerative colitis. We are pleased to have recently strengthened our leadership team, appointing Celia Economides as CFO and David Rubenstein, M.D., Ph.D., as Chief Scientist. Dr. Rubenstein led the development and FDA approval of the first AhR agonist. We have further added to our depth of experience through the appointment of new Board members who bring inflammatory disease, clinical development and company building expertise to Azora. Our focus now is execution excellence, and we remain on track to submit an IND for AT177 and initiate our Phase 1a trial in the first half of 2027.”

Matt Davidson, Ph.D., President, Co-Founder and Chief Executive Officer
4:08 PM ET 8-K
Financial Results Evommune, Inc. EVMN

Evommune Financial Results

Evommune, Inc. reported financial results for the third quarter ended September 30, 2026, and provided a business update on its immunology pipeline. The company highlighted the in-licensing of EVO570, positive Phase 2a data for EVO301 in atopic dermatitis, and confirmed a cash runway extending into the second half of 2029.

“We have built a portfolio of differentiated immunology assets spanning biologics and small molecules, each aimed at a distinct upstream driver of chronic inflammation. The in-licensing of EVO570 expands our reach into T- and B-cell-driven autoimmune diseases, while the EADV data strengthen our conviction that EVO301 has the potential to become a foundational therapy in atopic dermatitis, if approved.”

Luis Peña, President and Chief Executive Officer

“As we advance EVO301 into Phase 2b and expand into ulcerative colitis, 2027 will be a year of execution and clinical catalysts for Evommune, with additional new clinical studies across EVO646 and EVO570 and Phase 2b migraine top-line data expected from EVO756. With a strong balance sheet and an experienced team, we believe we are well positioned to deliver on these milestones and create meaningful value for patients and stockholders.”

Luis Peña, President and Chief Executive Officer
4:08 PM ET Form 4
Insider Selling Intapp, Inc. INTA

Intapp Insider Nancy L. Harris Sells $290K of Stock

Nancy L. Harris sold 6,512 shares of Intapp, Inc. at $43.77 to $45.00 a share (average $44.56) in 3 transactions, worth $290K in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 34,907 (-8.5%).

Value
$290K
Shares
6,512
Average price
$44.56
Holding change
-8.5%
Trade date
Nov 9, 2026 to Nov 10, 2026
4:08 PM ET 10-Q
Financial Results Airo Group Holdings, Inc. AIRO

Airo Group Holdings Q3 2026 Results: Net Loss of $12M, Loss Widens

AIRO Group Holdings reported revenue of $69.6 million for the nine months ended September 30, 2026, a significant increase from $42.6 million in the prior year period. Despite higher gross profits, the company incurred a net loss of $29.4 million due to increased research and development and general administrative expenses.

Key figure
Net loss $12M
4:08 PM ET 10-Q
Financial Results BioCardia, Inc. BCDA ▶ Call

BioCardia Q3 2026 Results: Net Loss of $1.82M, Loss Widens

BioCardia, Inc. reported a net loss of $5.7 million for the nine months ended September 30, 2026, compared to a $6.2 million loss in the prior year period. The company ended the quarter with $2.2 million in cash and cash equivalents, supported by $5.3 million in proceeds from common stock sales during the year.

Key figure
Net loss $1.82M
4:08 PM ET 10-Q
Financial Results Cyngn Inc. CYN

Cyngn Q3 2026 Results: Net Loss of $5.96M, Loss Narrows

Cyngn Inc. reported a net loss of $18.8 million for the nine months ended September 30, 2026, compared to $17.8 million in the prior year period, despite a significant increase in revenue to $405,527. The company strengthened its cash position through $17.9 million in financing activities, including at-the-market and public stock offerings, ending the period with $3.1 million in cash and $31.8 million in short-term investments.

Key figure
Net loss $5.96M
4:08 PM ET 10-Q
Financial Results Knightscope, Inc. KSCP

Knightscope Q3 2026 Results: Net Loss of $11.8M, Loss Widens

Knightscope, Inc. reported a significant decrease in cash and cash equivalents from $20.6 million at the end of 2025 to $6.8 million as of September 30, 2026. The company's total assets increased to $52.2 million, primarily driven by a substantial rise in goodwill and intangible assets following acquisitions, while management expressed substantial doubt about the company's ability to continue as a going concern.

Key figure
Net loss $11.8M
4:08 PM ET 10-Q
Financial Results United States Antimony Corp UAMY ▶ Call

United States Antimony Q3 2026 Results: Net Loss of $9.53M, Loss Widens

United States Antimony Corp reported a significant increase in net loss to $20.7 million for the nine months ended September 30, 2026, compared to $4.1 million in the prior year, driven by a sharp rise in operating expenses and mineral exploration costs. Despite the loss, the company strengthened its balance sheet through common stock issuances, ending the period with $171.9 million in total stockholders' equity.

Key figure
Net loss $9.53M
4:08 PM ET 10-Q
Financial Results Relmada Therapeutics, Inc. RLMD

Relmada Therapeutics Q3 2026 Results: Net Loss of $13.9M, Loss Widens

Relmada Therapeutics reported a net loss of $45.8 million for the nine months ended September 30, 2026, compared to $37.5 million in the prior year, driven by increased research and development costs. The company significantly strengthened its balance sheet through common stock issuances, ending the period with $202.1 million in cash and short-term investments.

Key figure
Net loss $13.9M
4:08 PM ET 8-K
Financial Results Cisco Systems, Inc. CSCO

Cisco Systems Financial Results

Cisco reported record first quarter fiscal 2027 revenue of $18.5 billion, a 24% increase year-over-year, driven by high demand for AI infrastructure and networking technology. The company raised its full-year fiscal 2027 revenue guidance to a range of $74.8 billion to $75.8 billion and increased its AI infrastructure revenue expectations from hyperscalers to $9 billion.

Term
Q1 2027

“In Q1, we delivered the strongest revenue and non-GAAP earnings per share growth rates for Cisco in over 15 years. Organizations are turning to Cisco for our trusted, market-defining technology and our expertise to help them scale, secure and optimize their environments for the agentic AI era. We are in the very early stages of a multi-year networking supercycle, and we're confident in our ability to continue capturing the multi-billion-dollar opportunity it represents for Cisco.”

Chuck Robbins, chair and CEO of Cisco

“Q1 FY27 was another record quarter for Cisco, with revenue, non-GAAP operating margin, and non-GAAP EPS all exceeding the high end of our guidance ranges. The strength of our Q1 performance gives us confidence to raise our revenue and non-GAAP EPS guidance for FY27. As our business continues to scale, we are unlocking significant operating leverage which is enabling us to grow earnings much faster than revenue. Looking ahead, we remain focused on delivering durable growth and driving continued capital returns.”

Mark Patterson, CFO of Cisco
4:08 PM ET Form 4
Insider Selling Gartner Inc IT

Gartner EVP, Bus. & Tech. Insights Yvonne Genovese Sells $99.7K of Stock

Yvonne Genovese, EVP, Bus. & Tech. Insights, sold 524 shares of Gartner Inc at $190.30 a share, worth $99.7K in total on Nov 9, 2026. Shares held after the trade: 5,684 (-8.4%).

Value
$99.7K
Shares
524
Price
$190.30
Role
EVP, Bus. & Tech. Insights
Holding change
-8.4%
Trade date
Nov 9, 2026
4:08 PM ET 8-K
Shareholder Meeting Genpact LTD G

Genpact Shareholder Meeting

Genpact Limited held a special general meeting of shareholders on November 10, 2026, where shareholders approved a proposal to change the company's jurisdiction of incorporation from Bermuda to the State of Delaware. The domestication involves discontinuing as a Bermuda exempted company and continuing as a Delaware corporation.

4:08 PM ET 8-K
Loan & Debt Hyatt Hotels Corp H

Hyatt Hotels $400M Debt Financing with Computershare Trust Company, N.A.

Hyatt Hotels Corporation completed a public offering of $400 million in 5.950% Senior Notes due 2033. The company received net proceeds of approximately $395.3 million, which it intends to use alongside excess cash to repay its outstanding 5.750% notes due 2027 and for general corporate purposes.

Value
$400M
Counterparty
Computershare Trust Company, N.A.
Term
through Nov 2033
4:08 PM ET 10-Q
Financial Results Vuzix Corp VUZI ▶ Call

Vuzix Q3 2026 Results: Net Loss of $8.39M, Loss Widens

Vuzix Corp reported total sales of $0.7 million for the quarter ended September 30, 2026, down from $1.2 million in the prior year period. The company experienced a net loss of $8.4 million for the quarter and $23.1 million for the first nine months of 2026, while maintaining a cash balance of $9.2 million.

Key figure
Net loss $8.39M
4:08 PM ET 10-Q
Financial Results AmpliTech Group, Inc. AMPG

AmpliTech Group Q3 2026 Results: Net Loss of $1.89M, Loss Widens

AmpliTech Group reported a net loss of $6.5 million for the nine months ended September 30, 2026, compared to a $3.8 million loss in the prior year period. Despite a slight decrease in nine-month revenue, the company significantly strengthened its balance sheet, increasing cash and marketable securities to over $30 million following successful rights and direct offerings.

Key figure
Net loss $1.89M
4:08 PM ET 10-Q
Financial Results EyePoint, Inc. EYPT ▶ Call

EyePoint Q3 2026 Results: Net Loss of $95.6M, Loss Widens

EyePoint, Inc. reported a significant increase in net loss to $274.9 million for the nine months ended September 30, 2026, driven primarily by a surge in research and development expenses to $237.4 million. Total revenues declined sharply from $30.8 million to $2.0 million year-over-year, largely due to the absence of significant license and collaboration revenue seen in 2025.

Key figure
Net loss $95.6M
4:08 PM ET 10-Q
Financial Results Rocket Pharmaceuticals, Inc. RCKT

Rocket Pharmaceuticals Q3 2026 Results: Net Loss of $49.2M, Loss Narrows

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on genetic medicines for rare diseases. As of September 30, 2026, the company is classified as a non-accelerated filer and smaller reporting company with 111,660,283 shares of common stock outstanding.

Key figure
Net loss $49.2M
4:08 PM ET 8-K
Financial Results HireQuest, Inc. HQI

HireQuest Financial Results

HireQuest reported third quarter 2026 financial results, with total revenue increasing 4.0% to $8.8 million. Net income decreased to $1.7 million, or $0.12 per diluted share, primarily due to a $1.3 million write-down of notes receivable related to the repossession of a franchised location.

Term
Q3 2026

“Our third quarter results reflect continued momentum across our core commercial staffing brands, as improving demand delivered another quarter of year-over-year revenue growth. Our franchise model continues to demonstrate its resilience, allowing us to grow alongside our franchisees as they benefit from a strengthened labor market.”

Rick Hermanns, HireQuest’s President and Chief Executive Officer

“We believe the improving demand environment we have seen throughout 2026 positions our franchisees well as we close out the year and look ahead to 2027. We have a strong balance sheet and ample liquidity, and we remain focused on disciplined capital allocation as we work to deliver consistently profitable results and enhanced value for our shareholders.”

Rick Hermanns, HireQuest’s President and Chief Executive Officer
4:08 PM ET Form 4
Insider Selling Zevia PBC ZVIA

Zevia PBC Director David J. Lee Sells $231K of Stock

David J. Lee, Director, sold 179,589 shares of Zevia PBC at $1.29 a share, worth $231K in total on Nov 9, 2026. Shares held after the trade: 100,373 (-64.1%).

Value
$231K
Shares
179,589
Price
$1.29
Role
Director
Holding change
-64.1%
Trade date
Nov 9, 2026
4:07 PM ET 8-K
Financial Results Solesence, Inc. SLSN

Solesence Financial Results

Solésence reported record third quarter 2026 financial results, with revenue increasing 38% year-over-year to $20.2 million. The company achieved its highest-ever quarterly net income of $3.7 million, driven by operational excellence and strong demand from brand partners.

Term
Q3 2026

“We’re very pleased that Solésence delivered solid top line growth as well as steady operational and strategic progress in the third quarter, driven by key milestones across our Transform and Transcend framework. Most notably, we reached a major turning point by completing the primary investment and implementation phase of our first pillar, operational excellence. This elevated capacity and efficiency position us to meet robust demand from our brand partners today while seamlessly scaling for tomorrow. Paired with our continued innovation in novel formulations and expanding global presence, Solésence is uniquely positioned to deliver long-term, profitable growth and lead the market in meeting evolving consumer needs.”

Kevin Cureton, President and CEO

“By pairing record revenue and net income with strong margin expansion, we have positioned Solésence for sustained growth. The operational and financial improvements achieved throughout 2026 provide a strong foundation as we look ahead to 2027.”

Laura Riffner, Chief Financial Officer
4:07 PM ET 8-K
Financial Results ADARx Pharmaceuticals, Inc. ADRX

ADARx Pharmaceuticals Financial Results

ADARx Pharmaceuticals reported Q3 2026 financial results, highlighting a cash position of $611.8 million following its IPO and concurrent private placement with AbbVie. The company is advancing three Phase 2 clinical trials for agazisiran and received FDA Fast Track designation for onvuzosiran in hereditary angioedema.

“We have made significant progress across our pipeline of next-generation siRNA therapeutics, bolstered by the successful completion of our IPO and concurrent private placement. These financings provide the resources to advance three clinical-stage programs in parallel, bring two advanced preclinical candidates into the clinic, and support additional IND filings as we expand our pipeline.”

Zhen Li, Ph.D., President and Chief Executive Officer of ADARx

“As the siRNA field evolves, we see tremendous opportunity to expand the range of diseases these therapeutics can address. We believe that our progress with differentiated liver-targeted programs and targeted delivery to extrahepatic tissues positions us to advance our mission of delivering life-changing treatments to patients with unmet medical needs.”

Zhen Li, Ph.D., President and Chief Executive Officer of ADARx
4:07 PM ET 10-Q
Financial Results Immix Biopharma, Inc. IMMX

Immix Biopharma Q3 2026 Results: Net Loss of $13.9M, Loss Widens

Immix Biopharma, Inc. reported a significant increase in cash and cash equivalents to $320.3 million as of September 30, 2026, compared to $93.9 million at year-end 2025. The company's accumulated deficit grew to $140.0 million, driven by nine-month operating expenses including $22.4 million in general and administrative costs and $16.9 million in research and development.

Key figure
Net loss $13.9M
4:07 PM ET 8-K
Financial Results Digimarc Corp DMRC

Digimarc Financial Results

Digimarc reported third quarter 2026 financial results, with total revenue of $6.4 million and a net loss of $8.1 million. The company noted that momentum is building with new customers in retail and CPG, though ARR decreased to $10.8 million primarily due to the expiration and step-down of two major commercial contracts.

“Last quarter we said our new execution focus was starting to show results. Since then, many of those results moved from pipeline to signed business earlier than expected, with new customers committing to our solutions across retail and CPG.”

Paul Carreiro, Digimarc CEO

“Our commercial leadership team is mostly in place, and our focus is clear: turn this momentum into recurring and predictable revenue growth in 2027.”

Paul Carreiro, Digimarc CEO
4:07 PM ET 8-K
Loan & Debt Zimmer Biomet Holdings, Inc. ZBH

Zimmer Biomet Holdings $500M Debt Financing with Barclays Capital Inc.

Zimmer Biomet Holdings, Inc. completed a dual-currency public offering of senior notes, consisting of $500 million of 5.850% notes due 2036 and €500 million of 4.375% notes due 2033. The proceeds are intended to be used for general corporate purposes, which may include the repayment of existing 2.425% notes due 2026 and 4.700% notes due 2027.

Value
$500M
Counterparty
Barclays Capital Inc.
Term
through 2036
4:07 PM ET 8-K
Financial Results Newsmax Inc. NMAX

Newsmax Financial Results

Newsmax reported record Q3 2026 revenue of $69.0 million, a 52.5% year-over-year increase, driven by strong affiliate fees and a $14 million service revenue termination fee. The company achieved net income of $15.2 million and Adjusted EBITDA of $19.0 million, marking its second consecutive profitable quarter. Additionally, the company announced the resignation of director Nancy G. Brinker and the appointment of Carla Sands to the Board.

Term
Q3 2026

“The third quarter was the strongest in our history as a public company. Setting aside the one-time revenue item, we delivered our fastest revenue growth since our listing and a second consecutive profitable quarter.”

Christopher Ruddy, Chief Executive Officer of Newsmax

“Our third quarter results reflect the operating leverage we are building across the business, with affiliate and licensing growth continuing to shift our revenue mix toward our highest-margin streams.”

Darryle Burnham, Chief Financial Officer of Newsmax
4:07 PM ET 8-K
Financial Results OpenWorld, Inc. OPNW

OpenWorld Financial Results

OpenWorld, Inc. reported its first quarterly results as a Nasdaq-listed company following its reverse takeover of VerifyMe. The company reported revenue of $7.4 million and a GAAP net loss of $10.2 million, highlighting a strategic shift toward high-margin real-world asset (RWA) tokenization which contributed $6.4 million to the quarterly revenue.

Term
Q3 2026

“Q3 2026 was a defining quarter as we completed our transition to the public markets and accelerated our evolution into a high-margin RWA platform and major deal-origination company.”

Matthew Shaw, Chairman and Chief Executive Officer

“Revenue from our RWA business grew from zero a year ago to more than $6 million in the 2026 third quarter and $9 million for the first nine months of the year, while we maintained exceptional gross margins of more than 80%.”

Matthew Shaw, Chairman and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.